# Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

> **NCT07512583** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 178 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TQB2930 injection+TQB2102 for injection

## Key facts

- **NCT ID:** NCT07512583
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-03
- **Final completion:** 2028-12
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07512583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07512583, "Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07512583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*